Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 1890978, 7 pages
https://doi.org/10.1155/2018/1890978
Review Article

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus

Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China

Correspondence should be addressed to Zhuo Li; ac.oohay@ouhz_elbon and Guixia Wang; nc.ude.ulj@861gnawg

Received 26 October 2017; Revised 16 February 2018; Accepted 18 March 2018; Published 7 May 2018

Academic Editor: Peter Bolli

Copyright © 2018 You Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Forslund, F. Hildebrand, T. Nielsen et al., “Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota,” Nature, vol. 528, no. 7581, pp. 262–266, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Sender, S. Fuchs, and R. Milo, “Revised estimates for the number of human and bacteria cells in the body,” PLoS Biology, vol. 14, no. 8, article e1002533, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. K.-A. Lê, Y. Li, X. Xu et al., “Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population,” Frontiers in Physiology, vol. 3, p. 496, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Cox, N. P. West, and A. W. Cripps, “Obesity, inflammation, and the gut microbiota,” The Lancet Diabetes & Endocrinology, vol. 3, no. 3, pp. 207–215, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. A. V. Hartstra, K. E. C. Bouter, F. Bäckhed, and M. Nieuwdorp, “Insights into the role of the microbiome in obesity and type 2 diabetes,” Diabetes Care, vol. 38, no. 1, pp. 159–165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Blandino, R. Inturri, F. Lazzara, M. Di Rosa, and L. Malaguarnera, “Impact of gut microbiota on diabetes mellitus,” Diabetes & Metabolism, vol. 42, no. 5, pp. 303–315, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. C. L. Boulange, A. L. Neves, J. Chilloux, J. K. Nicholson, and M. E. Dumas, “Impact of the gut microbiota on inflammation, obesity, and metabolic disease,” Genome Medicine, vol. 8, no. 1, p. 42, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Perry, L. Peng, N. A. Barry et al., “Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome,” Nature, vol. 534, no. 7606, pp. 213–217, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Plovier, A. Everard, C. Druart et al., “A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice,” Nature Medicine, vol. 23, no. 1, pp. 107–113, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Sato, A. Kanazawa, F. Ikeda et al., “Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes,” Diabetes Care, vol. 37, no. 8, pp. 2343–2350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” Nature, vol. 490, no. 7418, pp. 55–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. F. H. Karlsson, V. Tremaroli, I. Nookaew et al., “Gut metagenome in European women with normal, impaired and diabetic glucose control,” Nature, vol. 498, no. 7452, pp. 99–103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Yan, B. Feng, P. Li, Z. Tang, and L. Wang, “Microflora disturbance during progression of glucose intolerance and effect of sitagliptin: an animal study,” Journal of Diabetes Research, vol. 2016, Article ID 2093171, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. A. P. Liou, M. Paziuk, J. M. Luevano, S. Machineni, P. J. Turnbaugh Jr., and L. M. Kaplan, “Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity,” Science Translational Medicine, vol. 5, no. 178, article 178ra141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. P. D. Cani, A. M. Neyrinck, F. Fava et al., “Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia,” Diabetologia, vol. 50, no. 11, pp. 2374–2383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Tian, B. Li, C. He et al., “Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota,” Food & Function, vol. 7, no. 9, pp. 3789–3797, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. K. L. Wickens, C. A. Barthow, R. Murphy et al., “Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial,” British Journal of Nutrition, vol. 117, no. 6, pp. 804–813, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Salonen, L. Lahti, J. Salojarvi et al., “Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men,” The ISME Journal, vol. 8, no. 11, pp. 2218–2230, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D. J. Reijngoud, and B. M. Bakker, “The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism,” Journal of Lipid Research, vol. 54, no. 9, pp. 2325–2340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Tan, C. McKenzie, M. Potamitis, A. N. Thorburn, C. R. Mackay, and L. Macia, “Chapter Three - the role of short-chain fatty acids in health and disease,” Advances in Immunology, vol. 121, pp. 91–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. L. J. McCreight, C. J. Bailey, and E. R. Pearson, “Metformin and the gastrointestinal tract,” Diabetologia, vol. 59, no. 3, pp. 426–435, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Khan and G. Jena, “Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin,” Chemico-Biological Interactions, vol. 254, pp. 124–134, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Gu, X. Wang, J. Li et al., “Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment,” Nature Communications, vol. 8, no. 1, p. 1785, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Wu, E. Esteve, V. Tremaroli et al., “Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug,” Nature Medicine, vol. 23, no. 7, pp. 850–858, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. T. M. Wolever and J. L. Chiasson, “Acarbose raises serum butyrate in human subjects with impaired glucose tolerance,” British Journal of Nutrition, vol. 84, no. 1, pp. 57–61, 2000. View at Google Scholar
  26. G. A. Weaver, C. T. Tangel, J. A. Krause et al., “Acarbose enhances human colonic butyrate production,” The Journal of Nutrition, vol. 127, no. 5, pp. 717–723, 1997. View at Publisher · View at Google Scholar
  27. F. Greenway, S. Wang, and M. Heiman, “A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report,” Beneficial Microbes, vol. 5, no. 1, pp. 29–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. J. H. Burton, M. Johnson, J. Johnson, D. S. Hsia, F. L. Greenway, and M. L. Heiman, “Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels,” Journal of Diabetes Science and Technology, vol. 9, no. 4, pp. 808–814, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. D. L. Longo, Harrison’s Principles of Internal Medicine, McGraw-Hill, New York, 18th edition, 2012.
  30. A. Napolitano, S. Miller, A. W. Nicholls et al., “Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus,” PLoS One, vol. 9, no. 7, article e100778, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. D. Fullerton, S. Galic, K. Marcinko et al., “Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin,” Nature Medicine, vol. 19, no. 12, pp. 1649–1654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. Duca, C. D. Côté, B. A. Rasmussen et al., “Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats,” Nature Medicine, vol. 21, no. 5, pp. 506–511, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, and M. J. Birnbaum, “Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP,” Nature, vol. 494, no. 7436, pp. 256–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Y. Hur and M. S. Lee, “New mechanisms of metformin action: focusing on mitochondria and the gut,” Journal of Diabetes Investigation, vol. 6, no. 6, pp. 600–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 35, no. 6, pp. 1364–1379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Florez, J. Luo, S. Castillo-Florez et al., “Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes,” Postgraduate Medicine, vol. 122, no. 2, pp. 112–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Dujic, K. Zhou, L. A. Donnelly, R. Tavendale, C. N. A. Palmer, and E. R. Pearson, “Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study,” Diabetes, vol. 64, no. 5, pp. 1786–1793, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. J. B. Buse, R. A. DeFronzo, J. Rosenstock et al., “The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies,” Diabetes Care, vol. 39, no. 2, pp. 198–205, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. C. J. Bailey, C. Wilcock, and J. H. B. Scarpello, “Metformin and the intestine,” Diabetologia, vol. 51, no. 8, pp. 1552-1553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Bonora, M. Cigolini, O. Bosello et al., “Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects,” Current Medical Research and Opinion, vol. 9, no. 1, pp. 47–51, 1984. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Cabreiro, C. Au, K. Y. Leung et al., “Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism,” Cell, vol. 153, no. 1, pp. 228–239, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Le Chatelier, T. Nielsen, J. Qin et al., “Richness of human gut microbiome correlates with metabolic markers,” Nature, vol. 500, no. 7464, pp. 541–546, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Lee and G. Ko, “Effect of metformin on metabolic improvement and gut microbiota,” Applied and Environmental Microbiology, vol. 80, no. 19, pp. 5935–5943, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. N. R. Shin, J. C. Lee, H. Y. Lee et al., “An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice,” Gut, vol. 63, no. 5, pp. 727–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. J. de la Cuesta-Zuluaga, N. T. Mueller, V. Corrales-Agudelo et al., “Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid–producing microbiota in the gut,” Diabetes Care, vol. 40, no. 1, pp. 54–62, 2017. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Zhang, Y. Zhao, J. Xu et al., “Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats,” Scientific Reports, vol. 5, no. 1, article 14405, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. The DECODE study group, European Diabetes Epidemiology Group, and Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe, “Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria,” The Lancet, vol. 354, no. 9179, pp. 617–621, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Nakagami and the DECODA Study Group, “Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin,” Diabetologia, vol. 47, no. 3, pp. 385–394, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. S. R. Joshi, E. Standl, N. Tong, P. Shah, S. Kalra, and R. Rathod, “Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review,” Expert Opinion on Pharmacotherapy, vol. 16, no. 13, pp. 1959–1981, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. W. Yang, J. Liu, Z. Shan et al., “Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial,” The Lancet Diabetes & Endocrinology, vol. 2, no. 1, pp. 46–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. J. L. Chiasson, R. G. Josse, R. Gomis et al., “Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial,” JAMA, vol. 290, no. 4, pp. 486–494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp, “Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies,” European Heart Journal, vol. 25, no. 1, pp. 10–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Chen, C. W. Chang, Y. C. Lin, J. T. Horng, and W. H. H. Sheu, “Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study,” Journal of Diabetes Research, vol. 2014, Article ID 812628, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Standl, M. J. Theodorakis, M. Erbach, O. Schnell, and J. Tuomilehto, “On the potential of acarbose to reduce cardiovascular disease,” Cardiovascular Diabetology, vol. 13, no. 1, p. 81, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Su, H. Liu, J. Li et al., “Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus,” Journal of Diabetes, vol. 7, no. 5, pp. 729–739, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Suzuki, M. Sano, K. Hayashida, I. Ohsawa, S. Ohta, and K. Fukuda, “Are the effects of α-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?” FEBS Letters, vol. 583, no. 13, pp. 2157–2159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. Chang, Y. C. Chang, J. W. Lin, S. T. Chen, L. M. Chuang, and M. S. Lai, “Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study,” The Journal of Clinical Endocrinology & Metabolism, vol. 100, no. 3, pp. 1121–1129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. X. Zhang, Z. Fang, C. Zhang et al., “Effects of acarbose on the gut microbiota of prediabetic patients: a randomized, double-blind, controlled crossover trial,” Diabetes Therapy, vol. 8, no. 2, pp. 293–307, 2017. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Panwar, D. Calderwood, I. R. Grant, S. Grover, and B. D. Green, “Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential,” European Journal of Nutrition, vol. 53, no. 7, pp. 1465–1474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Everard and P. D. Cani, “Gut microbiota and GLP-1,” Reviews in Endocrine and Metabolic Disorders, vol. 15, no. 3, pp. 189–196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. B. S. Samuel, A. Shaito, T. Motoike et al., “Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 43, pp. 16767–16772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. K. Nøhr, M. H. Pedersen, A. Gille et al., “GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes,” Endocrinology, vol. 154, no. 10, pp. 3552–3564, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. G. Tolhurst, H. Heffron, Y. S. Lam et al., “Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2,” Diabetes, vol. 61, no. 2, pp. 364–371, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Yang, H. Fukui, H. Eda et al., “Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility,” American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 312, no. 4, pp. G367–G373, 2017. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Grasset, A. Puel, J. Charpentier et al., “A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism,” Cell Metabolism, vol. 26, no. 1, p. 278, 2017. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Li, L. Han, M. Xu, J. Guo, M. Feng, and X. Wang, “The primary research on the gut microbes in KKAy mice,” Indian Journal of Microbiology, vol. 54, no. 1, pp. 12–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Xu, F. Hong, J. Wang et al., “DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis,” Biochimica et Biophysica Acta (BBA) – General Subjects, vol. 1861, no. 11, Part A, pp. 2690–2701, 2017. View at Publisher · View at Google Scholar · View at Scopus
  68. Q. Zhang, X. Xiao, M. Li et al., “Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats,” PLoS One, vol. 12, no. 10, article e0184735, 2017. View at Publisher · View at Google Scholar · View at Scopus
  69. D. R. Powell, M. Smith, J. Greer et al., “LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)–mediated absorption of intestinal glucose,” The Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 2, pp. 250–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Lehmann and P. J. Hornby, “Intestinal SGLT1 in metabolic health and disease,” American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 310, no. 11, pp. G887–G898, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. L. D. Pound, C. Patrick, C. E. Eberhard et al., “Cathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration, and selected gut bacteria,” Diabetes, vol. 64, no. 12, pp. 4135–4147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. X. Mei, X. Zhang, Z. Wang et al., “Insulin sensitivity-enhancing activity of phlorizin is associated with lipopolysaccharide decrease and gut microbiota changes in obese and type 2 diabetes (db/db) mice,” Journal of Agricultural and Food Chemistry, vol. 64, no. 40, pp. 7502–7511, 2016. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Sasaki, N. Ogasawara, Y. Funaki et al., “Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study,” BMC Gastroenterology, vol. 13, no. 1, p. 81, 2013. View at Publisher · View at Google Scholar · View at Scopus